rebuffed

Washington: The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp’s bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was invalidated amid a legal dispute with China’s HEC Pharm Co Ltd. The justices turned away an appeal by Novartis of a lower court’s decision to cancel the patent, a […] More